PD-1/PD-L1, MDSC Pathways, and Checkpoint Inhibitor Therapy in <i>Ph</i>(-) Myeloproliferative Neoplasm: A Review
There has been significant progress in immune checkpoint inhibitor (CPI) therapy in many solid tumor types. However, only a single failed study has been published in treating <i>Ph(</i>-) myeloproliferative neoplasm (MPN). To make progress in CPI studies on this disease, herein, we revie...
Main Authors: | Jen-Chin Wang, Lishi Sun |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-05-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/23/10/5837 |
Similar Items
-
Prognostic stratification based on the levels of tumor-infiltrating myeloid-derived suppressor cells and PD-1/PD-L1 axis in locally advanced rectal cancer
by: Yu Jin Lim, et al.
Published: (2022-10-01) -
Regional Delivery of Anti-PD-1 Agent for Colorectal Liver Metastases Improves Therapeutic Index and Anti-Tumor Activity
by: Louis F. Chai, et al.
Published: (2021-07-01) -
Disruption of Her2-Induced PD-L1 Inhibits Tumor Cell Immune Evasion in Patient-Derived Gastric Cancer Organoids
by: Jayati Chakrabarti, et al.
Published: (2021-12-01) -
Heat Shock Proteins and PD-1/PD-L1 as Potential Therapeutic Targets in Myeloproliferative Neoplasms
by: Steven De Almeida, et al.
Published: (2020-09-01) -
Myeloid-Derived Suppressor Cells (MDSC) in Melanoma Patients Treated with Anti-PD-1 Immunotherapy
by: Katarzyna Tomela, et al.
Published: (2023-03-01)